UK Firms Compete for NHS Contract to Replace Palantir

Deep News11-16 15:31

Multiple British companies are competing to take over from Palantir (NASDAQ: PLTR) in providing a data platform for the UK's National Health Service (NHS). This follows government signals that a lucrative healthcare data contract will be re-tendered under terms more favorable to domestic firms.

At least two competing groups are preparing bids as UK government ministers work on new procurement procedures that could result in the American tech company losing its contract to operate the NHS Federated Data Platform (FDP). Palantir's role in UK public healthcare has previously sparked strong opposition.

The UK government is expected to rule out triggering an early termination clause that would have allowed the NHS to end its partnership with Palantir by next March. Instead, ministers will announce the launch of a new procurement process enabling British alternative suppliers to bid for the 330 million pound contract.

On Monday, a consortium led by UK firms and comprising more than 20 companies announced it would bid to take over operation of the data platform, which is designed to integrate different categories of patient data to improve healthcare efficiency. Shane Tickell, head of healthcare consultancy Temple Black which leads the consortium, said: "I don't think Palantir can provide value for money for the NHS." He added that the UK has "an existing pool of domestic suppliers who have accumulated decades of experience on the front lines of UK public healthcare."

The consortium, named Drystone Health AI Collaboration, includes Voror Health Technologies and Black Pear Software. Both are NHS contractors that previously participated in the FDP contract bidding but ultimately lost to Palantir. Tickell said the consortium is larger and has stronger capital backing compared to previous UK-led bidding teams. Members also include the UK division of Toronto Stock Exchange-listed VitalHub, and IMS Maxims, a subsidiary of Toronto-listed Constellation Software.

The consortium will face competition from London-based tech company Quantexa, which is reportedly preparing to re-bid. Quantexa participated in the bidding when the FDP contract was first awarded three years ago but ultimately lost. If the UK government decides to select a domestic firm, Quantexa is viewed as the most promising candidate. Quantexa currently holds contracts with HM Revenue & Customs (HMRC), as well as major banks including HSBC and Standard Chartered. The company is expected to emphasize its existing NHS cooperation projects in Cheshire and Merseyside, along with its 2023 bidding experience, to demonstrate its capability to take over FDP platform operations. Quantexa is also reportedly willing to accept a cooperation model in which different companies handle platform operations in different NHS regions.

Palantir may also seek to retain the contract. The company could argue that since its employees working on the NHS project are all based in the UK, it should be recognized as a British company. UK government ministers are working on a new definition of "British supplier" in government procurement, with relevant standards expected to be introduced before the NHS formally launches its procurement process. Oracle Health, the healthcare division of American software company Oracle, is also seen as a potential bidder. The company reached the final stage of the 2023 procurement process. However, Oracle Health may also face questions about whether it can promote UK technological autonomy in healthcare technology.

Due to Palantir's partnerships with US immigration enforcement agencies and Israeli military intelligence, the UK government has faced increasing pressure over its agreement with the company, with critics including activists, Labour MPs, and healthcare professionals. Unison, the UK's largest public sector union, is also urging the government to replace Palantir with a domestic supplier. The union says its NHS members who use the FDP platform are not satisfied with its performance. Unison General Secretary Andrea Egan described the platform as "technically and morally bankrupt." In a survey sent to union members on Thursday, Egan said: "The NHS has the technical capability to build and operate its own data systems. These systems should be publicly owned and accountable to patients." She added: "Government ministers should invest in developing these professional capabilities rather than handing over sovereignty of our most sensitive data to an American private surveillance company."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment